New Case Study: Boston Medical Center Health System Specialty Pharmacy Program
Key Takeaways
- An integrated specialty pharmacy program can improve hospital operating margins while expanding patient access to care. Boston Medical Center Health System leveraged its specialty pharmacy program and 340B savings strategy to create a sustainable revenue source that helped strengthen financial performance and support its mission as a safety-net health system.
- Specialty pharmacy liaison models improve medication access, care coordination, and patient outcomes. By embedding pharmacy experts within clinical care teams, hospitals can help patients navigate complex specialty medication therapies, improve treatment adherence and achieve better clinical outcomes.
- Optimizing 340B resources and specialty pharmacy services helps health systems better serve vulnerable populations. Through strategic pharmacy investments, health systems can reinvest savings into patient care programs, improve access to specialty medications and deliver higher-quality care to underserved communities.
For several years in a row, Boston Medical Center Health System (BMCHS) was experiencing potentially detrimental operating losses. In 2014, the time was right for the system to create a specialty pharmacy program that would not only give back to the community, but would recharge their financial situation.
As a safety net and disproportionate share hospital, BMCHS’s 340B eligibility provides the opportunity to stretch limited financial resources to better serve their community. Along with optimizing 340B drug savings and making significant operational improvements, BMCHS developed a revenue-generating specialty pharmacy program based on a liaison model enabling pharmacy experts to partner with providers, nurses, care managers and other staff to support patients on specialty medication therapies.
Download an insightful case study on how Boston Medical Center Health System made changes that led to major improvements in system operating margins, patient access to specialty medications, and disease response and other clinical outcomes.